Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | IGF2R | P11717 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362008 | 1.00 | FBP1 (0.53) | FBP1AMDHD2PYGBGAAATIC | |
| SCHEMBL849806 | 1.00 | FBP1 (0.53) | FBP1AMDHD2PYGBGAAATIC | |
| SCHEMBL13176580 | 1.00 | FBP1 (0.53) | FBP1AMDHD2PYGBGAAATIC | |
| SCHEMBL29975460 | 0.93 | FBP1 (0.44) | FBP1AMDHD2PYGBGAAATIC | |
| SCHEMBL850489 | 0.86 | FBP1 (0.51) | FBP1AMDHD2ATICIGF2R | |
| SCHEMBL29601624 | 0.86 | FBP1 (0.51) | FBP1AMDHD2ATICIGF2R | |
| SCHEMBL13153881 | 0.83 | PYGB (0.48) | PYGBGAA | |
| SCHEMBL12918448 | 0.83 | PYGB (0.48) | PYGBGAA | |
| SCHEMBL4366341 | 0.81 | FBP1 (0.58) | FBP1AMDHD2PYGBGAAATIC | |
| SCHEMBL4366354 | 0.81 | FBP1 (0.58) | FBP1AMDHD2PYGBGAAATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026042726-A1 | EMBRYO ACQUISITION METHOD | 学校法人金沢医科大学 | 2026-02-26 | — | — | WO | claimed |
| US-20250297244-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SEVERE COVID 19 AND OTHER INFLAMMATORY AUTOIMMUNE DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2023215913-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SEVERE COVID 19 AND OTHER INFLAMMATORY AUTOIMMUNE DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-11-09 | — | — | WO | claimed |
| CN-110540370-B | Deplating process for panel glass electro-plated film layer | 蓝思科技（长沙）有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-110540369-B | Deplating liquid for deplating FGAR film and preparation method and application thereof | 蓝思科技（长沙）有限公司 | 2022-02-22 | — | — | CN | claimed |
| WO-2026042726-A1 | EMBRYO ACQUISITION METHOD | 学校法人金沢医科大学 | 2026-02-26 | — | — | WO | disclosed |
| WO-2026042727-A1 | EMBRYO ACQUISITION METHOD | 学校法人金沢医科大学 | 2026-02-26 | — | — | WO | disclosed |
| US-12558424-B2 | T cells having enhanced anti-tumor activity | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250295749-A1 | INACTIVATED STAPHYLOCOCCUS COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOLOGICAL MIMETICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250297244-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SEVERE COVID 19 AND OTHER INFLAMMATORY AUTOIMMUNE DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-09-25 | — | — | US | disclosed |
| CN-119912442-A | 2, 4-Disubstituted thiadiazole derivatives and their use as GLS1 inhibitors | 四川大学华西医院 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-111368435-B | Uncertain demand-oriented air separation pipe network device starting and stopping and load scheduling method | 浙江大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-110540370-B | Deplating process for panel glass electro-plated film layer | 蓝思科技（长沙）有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-110540370-B | Deplating process for panel glass electro-plated film layer | 蓝思科技（长沙）有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-110540369-B | Deplating liquid for deplating FGAR film and preparation method and application thereof | 蓝思科技（长沙）有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-110540369-B | Deplating liquid for deplating FGAR film and preparation method and application thereof | 蓝思科技（长沙）有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-110540369-B | Deplating liquid for deplating FGAR film and preparation method and application thereof | 蓝思科技（长沙）有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558424-B2 | T cells having enhanced anti-tumor activity | IL2, LDHB, LDHA | FBP1 1096/4885AMDHD2 865/4885PYGB 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.